Found: 142
Select item for more details and to access through your institution.
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry.
- Published in:
- Drugs - Real World Outcomes, 2024, v. 11, n. 3, p. 451, doi. 10.1007/s40801-024-00439-w
- By:
- Publication type:
- Article
650 - Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.029
- By:
- Publication type:
- Article
698 - Impact of amlitelimab (an anti-OX40 ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.072
- By:
- Publication type:
- Article
651 - Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.030
- By:
- Publication type:
- Article
721 - Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.094
- By:
- Publication type:
- Article
722 - Efficacy of povorcitinib for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 subgroup analysis from a randomized, placebo-controlled, phase 2b clinical trial.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.095
- By:
- Publication type:
- Article
693 - Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.067
- By:
- Publication type:
- Article
661 - Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.039
- By:
- Publication type:
- Article
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2139, doi. 10.1007/s13555-024-01219-8
- By:
- Publication type:
- Article
Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 8, p. 856, doi. 10.1001/jamadermatol.2024.2131
- By:
- Publication type:
- Article
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. 1543, doi. 10.1111/jdv.19925
- By:
- Publication type:
- Article
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 4, p. 669, doi. 10.1007/s40257-024-00855-2
- By:
- Publication type:
- Article
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1849, doi. 10.1007/s13555-024-01183-3
- By:
- Publication type:
- Article
Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
- Published in:
- Allergy, 2024, v. 79, n. 6, p. 1560, doi. 10.1111/all.16108
- By:
- Publication type:
- Article
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis.
- Published in:
- Frontiers in Medicine, 2024, p. 1, doi. 10.3389/fmed.2024.1292406
- By:
- Publication type:
- Article
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 5, p. 668, doi. 10.1093/bjd/ljae014
- By:
- Publication type:
- Article
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1145, doi. 10.1007/s13555-024-01158-4
- By:
- Publication type:
- Article
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 933, doi. 10.1007/s13555-024-01136-w
- By:
- Publication type:
- Article
Rapid resolution of guttate psoriasis without recurrence for one year following two doses of guselkumab.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 4, p. 534, doi. 10.1111/ijd.17055
- By:
- Publication type:
- Article
Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis.
- Published in:
- Clinical & Experimental Dermatology, 2024, v. 49, n. 3, p. 272, doi. 10.1093/ced/llad361
- By:
- Publication type:
- Article
Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
- Published in:
- Arthritis Research & Therapy, 2024, v. 26, p. 1, doi. 10.1186/s13075-023-03257-7
- By:
- Publication type:
- Article
Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii8, doi. 10.1093/bjd/ljad498.010
- By:
- Publication type:
- Article
Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii10, doi. 10.1093/bjd/ljad498.013
- By:
- Publication type:
- Article
Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD).
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii24, doi. 10.1093/bjd/ljad498.028
- By:
- Publication type:
- Article
Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2, and Heads Up studies.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii29, doi. 10.1093/bjd/ljad498.032
- By:
- Publication type:
- Article
Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii35, doi. 10.1093/bjd/ljad498.037
- By:
- Publication type:
- Article
Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii48, doi. 10.1093/bjd/ljad498.050
- By:
- Publication type:
- Article
Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii49, doi. 10.1093/bjd/ljad498.051
- By:
- Publication type:
- Article
Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii66, doi. 10.1093/bjd/ljad498.067
- By:
- Publication type:
- Article
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 1, p. 139, doi. 10.1007/s40257-023-00817-0
- By:
- Publication type:
- Article
Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
The Best Psoriasis Medications Emerge.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 1, p. 99, doi. 10.1001/jamadermatol.2023.4445
- By:
- Publication type:
- Article
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3031, doi. 10.1007/s13555-023-01054-3
- By:
- Publication type:
- Article
Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
- Published in:
- Journal of Dermatology, 2023, v. 50, n. 12, p. 1523, doi. 10.1111/1346-8138.16975
- By:
- Publication type:
- Article
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 6, p. 913, doi. 10.1007/s40257-023-00809-0
- By:
- Publication type:
- Article
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 6, p. 939, doi. 10.1007/s40257-023-00806-3
- By:
- Publication type:
- Article
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2911, doi. 10.1007/s13555-023-01015-w
- By:
- Publication type:
- Article
Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis.
- Published in:
- Journal of Psoriasis & Psoriatic Arthritis, 2023, v. 8, n. 4, p. 156, doi. 10.1177/24755303231201336
- By:
- Publication type:
- Article
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 8, p. 3410, doi. 10.1007/s12325-023-02568-0
- By:
- Publication type:
- Article
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 132, doi. 10.1093/bjd/ljad081
- By:
- Publication type:
- Article
Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities.
- Published in:
- Journal of Psoriasis & Psoriatic Arthritis, 2023, v. 8, n. 3, p. 100, doi. 10.1177/24755303231160683
- By:
- Publication type:
- Article
388 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.014
- By:
- Publication type:
- Article
427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.047
- By:
- Publication type:
- Article
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 6, p. 740, doi. 10.1093/bjd/ljad022
- By:
- Publication type:
- Article
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 6, p. 596, doi. 10.1001/jamadermatol.2023.0627
- By:
- Publication type:
- Article
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 3, p. 330, doi. 10.1093/bjd/ljac089
- By:
- Publication type:
- Article
Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 3, p. 185, doi. 10.1007/s40261-022-01240-9
- By:
- Publication type:
- Article
308 Tralokinumab provides other clinically meaningful improvements in adolescents with moderate-to-severe atopic dermatitis who did not achieve IGA 0/1 at week 16.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii5, doi. 10.1093/bjd/ljac140.008
- By:
- Publication type:
- Article
309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii6, doi. 10.1093/bjd/ljac140.009
- By:
- Publication type:
- Article